Drugs / Vincristine Liposomal
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03519984 | May 2018 → Nov 2020 | Philadelphia-positive myelogenous leukemia, T-cell acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +1 | University of Southern California | Terminated | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT03504644 | Aug 2018 → Jul 2025 overdue | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | ECOG-ACRIN Cancer Research Group | Active not recruiting | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vincristine Liposomal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03504644 ↗ |
| Route | Intravenous | “Patients also receive vincristine liposomal intravenously (IV) over 1 hour weekly for 4 weeks starting on day 15 of cycle 1.” NCT03504644 ↗ |